Knowledge Base Wiki

Search for LIMS content across all our Wiki Knowledge Bases.

Type a search term to find related articles by LIMS subject matter experts gathered from the most trusted and dynamic collaboration tools in the laboratory informatics industry.

Mafenide
Clinical data
Trade namesSulfamylon, Mafylon
AHFS/Drugs.comMonograph
Routes of
administration
Topical
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 4-(Aminomethyl)benzenesulfonamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.004.843 Edit this at Wikidata
Chemical and physical data
FormulaC7H10N2O2S
Molar mass186.23 g·mol−1
3D model (JSmol)
  • O=S(=O)(c1ccc(cc1)CN)N
  • InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11) checkY
  • Key:TYMRLRRVMHJFTF-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Mafenide (INN; usually as mafenide acetate, trade name Sulfamylon) is a sulfonamide-type medication used as an antibiotic. It was approved by the FDA in 1948.[citation needed]

Uses

Mafenide is used to treat severe burns.[1][2] It is used topically as an adjunctive therapy for second- and third-degree burns. It is bacteriostatic against many gram-positive and gram-negative organisms, including Pseudomonas aeruginosa. Some sources state that mafenide is more appropriate for non-facial burns, while chloramphenicol/prednisolone or bacitracin are more appropriate for facial burns.[3]

Mechanism of action

Mafenide works by reducing the bacterial population present in the avascular tissues of burns and permits spontaneous healing of deep partial-thickness burns. [citation needed]

Adverse reactions

Adverse reactions can include superinfection, pain or burning upon application, rash, pruritus, tachypnea, or hyperventilation. Mafenide is metabolized to a carbonic anhydrase inhibitor, which could potentially result in metabolic acidosis.[4]

Drug interactions

There are no significant interactions.[citation needed]

Contraindications

Mafenide is contraindicated in those with sulfonamide hypersensitivity or renal impairment.

Dosage

For use as adjunctive therapy for second- and third-degree burns to prevent infection, adults and children should apply topically to a thickness of approximately 1.6 mm to cleaned and debrided wound once or twice per day with a sterile gloved hand. The burned area should be covered with cream at all times.[citation needed]

References

  1. ^ Siuda JF, Cihonski CD (November 1972). "New compounds: carbamate derivatives of mafenide (homosulfanilamide)". Journal of Pharmaceutical Sciences. 61 (11): 1856–1857. doi:10.1002/jps.2600611143. PMID 4652670.
  2. ^ Haynes BW (June 1971). "Mafenide acetate in burn treatment". The New England Journal of Medicine. 284 (23): 1324. doi:10.1056/NEJM197106102842310. PMID 5576444.
  3. ^ Haik J, Ashkenazy O, Sinai S, Tessone A, Barda Y, Winkler E, et al. (November 2005). "Burn care standards in Israel: lack of consensus". Burns. 31 (7): 845–849. doi:10.1016/j.burns.2005.04.012. PMID 15967581.
  4. ^ "Sulfamylon (Mafenide Acetate)". RxList. Retrieved 22 December 2022.